202 related articles for article (PubMed ID: 2650904)
1. Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients.
Colombo N; Speyer JL; Green M; Canetta R; Beller U; Wernz JC; Meyers M; Widman T; Blum RH; Piccart M
Cancer Chemother Pharmacol; 1989; 23(5):323-8. PubMed ID: 2650904
[TBL] [Abstract][Full Text] [Related]
2. Prediction of hematologic toxicity of carboplatin by creatinine clearance rate.
Taguchi J; Saijo N; Miura K; Shinkai T; Eguchi K; Sasaki Y; Tamura T; Sakurai M; Minato K; Fujiwara Y
Jpn J Cancer Res; 1987 Sep; 78(9):977-82. PubMed ID: 3117753
[TBL] [Abstract][Full Text] [Related]
3. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.
Anderson H; Wagstaff J; Crowther D; Swindell R; Lind MJ; McGregor J; Timms MS; Brown D; Palmer P
Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1471-9. PubMed ID: 3053207
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule.
Joss RA; Kaplan S; Goldhirsch A; Sessa C; Brunner KW; Cavalli F
Invest New Drugs; 1984; 2(3):297-304. PubMed ID: 6392147
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma.
Evans BD; Raju KS; Calvert AH; Harland SJ; Wiltshaw E
Cancer Treat Rep; 1983 Nov; 67(11):997-1000. PubMed ID: 6315233
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy.
Speyer JL; Beller U; Colombo N; Sorich J; Wernz JC; Hochster H; Green M; Porges R; Muggia FM; Canetta R
J Clin Oncol; 1990 Aug; 8(8):1335-41. PubMed ID: 2199620
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of carboplatin (CBDCA) in children with cancer.
Bacha DM; Caparros-Sison B; Allen JA; Walker R; Tan CT
Cancer Treat Rep; 1986 Jul; 70(7):865-9. PubMed ID: 3521846
[TBL] [Abstract][Full Text] [Related]
8. A dose escalation study of carboplatin and ifosfamide in advanced ovarian cancer.
Gallagher CJ; Wiltshaw E; Coleman RE; Harper PG
Cancer Chemother Pharmacol; 1989; 24(1):54-7. PubMed ID: 2655961
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin combined with carboplatin: a new way of intensification of platinum dose in the treatment of advanced ovarian cancer. Belgian Study Group for Ovarian Carcinoma.
Piccart MJ; Nogaret JM; Marcelis L; Longrée H; Ries F; Kains JP; Gobert P; Domange AM; Sculier JP; Gompel C
J Natl Cancer Inst; 1990 Apr; 82(8):703-7. PubMed ID: 2181152
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
11. High-dose carboplatin in refractory ovarian cancer patients.
Ozols RF; Ostchega Y; Curt G; Young RC
J Clin Oncol; 1987 Feb; 5(2):197-201. PubMed ID: 3543243
[TBL] [Abstract][Full Text] [Related]
12. High dose cisplatin and high dose carboplatin in refractory ovarian cancer.
Ozols RF; Behrens BC; Ostchega Y; Young RC
Cancer Treat Rev; 1985 Sep; 12 Suppl A():59-65. PubMed ID: 3910223
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens.
Edmonson JH; McCormack GM; Wieand HS; Kugler JW; Krook JE; Stanhope CR; Everson LK; Laurie JA; Ebbert LP; Malkasian GD
J Natl Cancer Inst; 1989 Oct; 81(19):1500-4. PubMed ID: 2674460
[TBL] [Abstract][Full Text] [Related]
14. A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide.
Belani CP; Egorin MJ; Abrams JS; Hiponia D; Eisenberger M; Aisner J; Van Echo DA
J Clin Oncol; 1989 Dec; 7(12):1896-902. PubMed ID: 2555452
[TBL] [Abstract][Full Text] [Related]
15. Prediction from creatinine clearance of thrombocytopenia and recommended dose in patients receiving (glycolato-O,O')-diammine platinum (II) (NSC 375101D).
Sasaki Y; Fukuda M; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Yamada K; Kojima A; Nakagawa K
Jpn J Cancer Res; 1990 Feb; 81(2):196-200. PubMed ID: 2110134
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of carboplatin (CBDCA) in small-cell and non-small-cell lung cancer with correlation to in vitro analysis of cytotoxicity.
Dmitrovsky E; Seifter EJ; Gazdar AF; Tsai CM; Edison M; Brantley P; Veach SR; Batist G; Ihde DC; Mulshine JL
Am J Clin Oncol; 1990 Aug; 13(4):285-9. PubMed ID: 2165737
[TBL] [Abstract][Full Text] [Related]
17. Iproplatin and carboplatin induced toxicities: overview of phase II clinical trial conducted by the EORTC Early Clinical Trials Cooperative Group (ECTG).
van Glabbeke M; Renard J; Pinedo HM; Cavalli F; Vermorken J; Sessa C; Abele R; Clavel M; Monfardini S
Eur J Cancer Clin Oncol; 1988 Feb; 24(2):255-62. PubMed ID: 3281842
[TBL] [Abstract][Full Text] [Related]
18. [Combined radiotherapy with cis- or carboplatin in advanced head and neck tumors].
Zamboglou N; Pape H; Schnabel T; Wurm R; Bannach B; Fürst G; Schmitt G
Strahlenther Onkol; 1989 Sep; 165(9):647-51. PubMed ID: 2678546
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer.
Gadducci A; Tana R; Teti G; Zanca G; Fanucchi A; Genazzani AR
Int J Gynecol Cancer; 2008; 18(4):615-20. PubMed ID: 18754135
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of carboplatin in small cell lung cancer.
Tamura T; Saijo N; Shinkai T; Eguchi K; Sasaki Y; Sakurai M; Fujiwara Y; Nakano H; Nakagawa K; Minato K
Jpn J Clin Oncol; 1988 Mar; 18(1):27-32. PubMed ID: 2832635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
